Begin with the outcome
BPC-157 and GHK-Cu are often discussed under the broad idea of tissue repair. Their best-known findings do not measure the same thing. An injured tendon carrying more force and a skin sample making more collagen are distinct results.
The rat Achilles-tendon experiment measured mechanical strength and function after a deliberately created injury. The topical GHK review concerns skin biology, cosmetic measures and problems with delivery through the skin.
Neither kind of result supplies a shared scale for ranking these compounds as treatments. The appropriate comparison is the study's population, preparation, route and measured outcome. Keeping those details together prevents a promising laboratory result from becoming an unsupported clinical claim.
Human evidence has different limits
A 2025 BPC-157 review describes a small set of human pilot reports rather than a large clinical program. A safety observation in two adults can identify what happened to those participants during observation. It cannot settle uncommon reactions or long-term effects.
GHK-Cu has human topical literature, but its size and quality vary. Some frequently repeated cosmetic findings are reported through reviews of older work. A study of a multi-ingredient preparation does not isolate GHK-Cu's contribution.
The route matters as much as the compound name. A topical study does not establish injection safety. Likewise, an animal injury experiment does not identify a personal dose or a timetable for human recovery. Missing data cannot be filled by placing several unlike studies alongside one another.
Blends add a separate question
Wolverine usually pairs BPC-157 and TB-500. GLOW usually adds GHK-Cu to that pairing. Neither name establishes a standardized clinical formula, and the cited sources do not establish the combined benefit or safety of either blend.
TB-500 also needs a careful identity check. Much of the supporting discussion concerns full-length thymosin beta-4, rather than its short fragment. The full-length protein review cannot establish an equivalent result for the fragment inside a blend.
A combined study would need to test the actual ingredients together. It would also need meaningful comparison groups to establish whether the pairing adds a benefit. Separate findings cannot demonstrate that interaction.
Research and access compared
This table summarizes two individual compounds before considering access. It describes the evidence, not a choice of treatment. Clinical suitability and the regulatory position are separate questions that the experiments cannot answer for a person.
| Question | BPC-157 | GHK-Cu |
|---|---|---|
| Main setting | Animal injury experiments; small human reports | Cell studies, skin tests and limited topical studies |
| Example outcome | Rat tendon strength and movement | Collagen production and cosmetic skin measures |
| Main limitation | Animal findings do not establish human recovery | Skin findings do not establish injection effects |
| Access context | Research findings do not determine prescribing | Route and individual assessment remain separate questions. |
The comparison shows why BPC-157 findings cannot settle a prescription decision. Prescription-only peptide care at Promise Peptides (mypromise.com) is limited to the U.S.; requests go to a licensed U.S. provider who reviews them and decides whether to prescribe. A compounded medicine has no FDA approval, and not everyone qualifies for care.
Questions the comparison cannot settle
Which compound works best?
There is no head-to-head clinical evidence here establishing a best option. The outcomes and routes are too different for a simple ranking. Even a positive result in a small study leaves open how it compares with established care or applies to a different condition.
Does a promising mechanism mean a safer treatment?
No. Effects on collagen, cell movement or blood vessels explain why researchers ask a question. They do not establish a favorable balance of benefit and harm. Safety requires observation in the relevant population using the actual preparation.
Does a prescription mean FDA approval?
A prescription and approval are different matters. Compounded medicines are not FDA-approved. The FDA safety-risk page, current as of April 22, 2026, lists BPC-157, injectable GHK-Cu and the thymosin beta-4 fragment as nominated but withdrawn. Withdrawal does not provide clearance.
Where are the detailed sources?
The references identify every source linked across these pages and explain what each contributes. The individual BPC-157, GHK-Cu, GLOW and Wolverine pages keep the relevant limitations beside their findings.